Asset sale Completed

LEO Pharma acquisition of global rights for MT-7117 (dersimelagon)

US$435m consideration

Announced Aug 2026

Advisers

Worldwide rights to dersimelagon

Target

Financial adviser

LEO Pharma

Acquirer

Target
Worldwide rights to dersimelagon
Acquirer
LEO Pharma
Seller
Tanabe Pharma
Buyer based in
Denmark
Seller based in
Japan
Completed
18 Aug 2026
Sector
Pharma
Tags
Pharma, Dermatology, Rare Disease

Similar deals

All pharma deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.